AU2004295104B2 - GAG binding proteins - Google Patents

GAG binding proteins Download PDF

Info

Publication number
AU2004295104B2
AU2004295104B2 AU2004295104A AU2004295104A AU2004295104B2 AU 2004295104 B2 AU2004295104 B2 AU 2004295104B2 AU 2004295104 A AU2004295104 A AU 2004295104A AU 2004295104 A AU2004295104 A AU 2004295104A AU 2004295104 B2 AU2004295104 B2 AU 2004295104B2
Authority
AU
Australia
Prior art keywords
protein
gag binding
modified
gag
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004295104A
Other languages
English (en)
Other versions
AU2004295104A1 (en
Inventor
Andreas J. Kungl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protaffin Biotechnologie AG
Original Assignee
Protaffin Biotechnologie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protaffin Biotechnologie AG filed Critical Protaffin Biotechnologie AG
Publication of AU2004295104A1 publication Critical patent/AU2004295104A1/en
Application granted granted Critical
Publication of AU2004295104B2 publication Critical patent/AU2004295104B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2004295104A 2003-12-04 2004-12-02 GAG binding proteins Ceased AU2004295104B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0195203A AT412785B (de) 2003-12-04 2003-12-04 Gag-bindungsproteine
ATA1952/2003 2003-12-04
PCT/EP2004/013670 WO2005054285A1 (en) 2003-12-04 2004-12-02 Gag binding proteins

Publications (2)

Publication Number Publication Date
AU2004295104A1 AU2004295104A1 (en) 2005-06-16
AU2004295104B2 true AU2004295104B2 (en) 2010-07-22

Family

ID=33494536

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004295104A Ceased AU2004295104B2 (en) 2003-12-04 2004-12-02 GAG binding proteins

Country Status (20)

Country Link
US (4) US7585937B2 (cg-RX-API-DMAC10.html)
EP (5) EP2311866A1 (cg-RX-API-DMAC10.html)
JP (3) JP4980721B2 (cg-RX-API-DMAC10.html)
KR (2) KR101188785B1 (cg-RX-API-DMAC10.html)
CN (1) CN1890264B (cg-RX-API-DMAC10.html)
AT (3) AT412785B (cg-RX-API-DMAC10.html)
AU (1) AU2004295104B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0416544A (cg-RX-API-DMAC10.html)
CA (1) CA2546789A1 (cg-RX-API-DMAC10.html)
CY (2) CY1109480T1 (cg-RX-API-DMAC10.html)
DE (1) DE602004022595D1 (cg-RX-API-DMAC10.html)
DK (2) DK1689775T3 (cg-RX-API-DMAC10.html)
ES (2) ES2330362T3 (cg-RX-API-DMAC10.html)
IL (1) IL175565A0 (cg-RX-API-DMAC10.html)
NZ (1) NZ547612A (cg-RX-API-DMAC10.html)
PL (2) PL1752470T3 (cg-RX-API-DMAC10.html)
PT (2) PT1752470E (cg-RX-API-DMAC10.html)
SG (1) SG149000A1 (cg-RX-API-DMAC10.html)
SI (2) SI1752470T1 (cg-RX-API-DMAC10.html)
WO (1) WO2005054285A1 (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
CN100366637C (zh) * 2005-11-17 2008-02-06 中国人民解放军第四军医大学 人白细胞介素8拮抗蛋白及其制备方法
US9422356B2 (en) * 2006-01-31 2016-08-23 Republic Of Korea (Republic Of National Fisheries Research And Development Institute) Artificial signal peptide for expressing an insoluble protein as a soluble active form
JP5173838B2 (ja) 2006-02-13 2013-04-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
EP1894571A1 (en) * 2006-08-29 2008-03-05 Protaffin Biotechnologie AG Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection
US20100075918A1 (en) * 2006-12-08 2010-03-25 Lokeshwar Vinata B Hyaluronidase inhibitors as anti-cancer agents
AT504685B1 (de) * 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
CA2686817A1 (en) * 2007-05-07 2009-02-19 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
EP2042516A1 (en) * 2007-09-27 2009-04-01 Protaffin Biotechnologie AG Glycosaminoglycan-antagonising MCP-1 mutants and methods of using same
EP2185719B1 (en) 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
EP2053060A1 (en) * 2007-10-24 2009-04-29 Protaffin Biotechnologie AG SDF-1-based glyocosaminoglycan antagonists and methods of using same
US8314212B2 (en) * 2008-02-08 2012-11-20 Lindsey Miles Plasminogen receptor PLG-RKT and antibodies thereof
US20120046218A1 (en) 2009-01-30 2012-02-23 Protaffin Biotechnologie Ag Glycosaminoglycan-antagonising mcp-i mutants and methods of using same
WO2011029931A1 (en) 2009-09-11 2011-03-17 Protaffin Biotechnologie Ag Composition for treatment of cxcl8-mediated lung inflammation
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
WO2012123585A1 (en) 2011-03-16 2012-09-20 Protaffin Biotechnologie Ag Fgfr1-based antagonists with improved glycosaminoglycan affinity and methods of using same
EP2729487A2 (en) 2011-07-08 2014-05-14 Protaffin Biotechnologie AG Novel sdf-1-based glycosaminoglycan antagonist and methods of using same
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
WO2014079957A1 (de) * 2012-11-23 2014-05-30 Bayer Cropscience Ag Selektive inhibition der ethylensignaltransduktion
US9493528B2 (en) * 2013-01-10 2016-11-15 Supadelixir Inc. Microphthalmia-associated transcription factor-derived peptide and composition containing same
WO2015110526A1 (en) * 2014-01-22 2015-07-30 Antagonis Biotherapeutics Gmbh Novel glycosaminoglycan-antagonising fusion proteins and methods of using same
WO2021038033A1 (en) 2019-08-29 2021-03-04 Antagonis Biotherapeutics Gmbh T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity
CN110791523B (zh) * 2019-12-13 2022-05-10 南京农业大学 一种棉花抗旱相关基因GhRCHY1及其应用
WO2023003984A2 (en) * 2021-07-20 2023-01-26 Oregon Health & Science University Label-free detection of protease activity
KR20250040765A (ko) * 2023-09-15 2025-03-25 (주)케어젠 펩타이드를 유효성분으로 하는 발모 촉진 또는 탈모증의 억제, 예방 또는 개선용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007935A1 (en) * 1990-11-01 1992-05-14 The Scripps Research Institute Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
WO1996034965A2 (en) * 1995-05-05 1996-11-07 Chiron Corporation Chimeric mcp and daf proteins with cell surface localizing domain
WO2002020715A2 (en) * 2000-09-05 2002-03-14 Biosight Ltd. Peptide conjugated anti-cancer prodrugs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960691A (en) * 1986-09-29 1990-10-02 Abbott Laboratories Chromatographic test strip for determining ligands or receptors
US5234911A (en) * 1990-07-09 1993-08-10 Gist-Brocades, N.V. Substance with interleukin-8 inhibiting activity and process for its preparation
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
JP2694321B2 (ja) * 1993-03-10 1997-12-24 大塚製薬株式会社 インターロイキン−1阻害剤
US5527546A (en) * 1994-08-10 1996-06-18 Bayer Corporation Human interleukin 6 inhibitor
JPH1045602A (ja) * 1996-07-31 1998-02-17 Motoyasu Murakami ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−8産生阻害剤
US6852696B2 (en) * 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
JP2003063980A (ja) * 2001-08-28 2003-03-05 Noevir Co Ltd Rantes産生阻害剤
US6982170B1 (en) * 2001-12-17 2006-01-03 Maine Medical Center Research Institute Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
JP2003306438A (ja) * 2002-02-18 2003-10-28 Shiseido Co Ltd ケモカイン発現阻害剤
JP2003267887A (ja) * 2002-03-15 2003-09-25 Shiseido Co Ltd ケモカイン発現抑制皮膚外用剤
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
CN1665839A (zh) * 2002-04-10 2005-09-07 应用研究系统Ars股份公司 Mcp蛋白质的新型拮抗剂
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007935A1 (en) * 1990-11-01 1992-05-14 The Scripps Research Institute Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
WO1996034965A2 (en) * 1995-05-05 1996-11-07 Chiron Corporation Chimeric mcp and daf proteins with cell surface localizing domain
WO2002020715A2 (en) * 2000-09-05 2002-03-14 Biosight Ltd. Peptide conjugated anti-cancer prodrugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUTCHER, D. J. et al., FEBS Letters, 1997, vol. 409, no. 2, pages 183-87 (X) *
ECKER, G., Osterreichische Apotheker-Zeitung, 2003, vol. 57, no. 14, 7 pages 658-60 *
JAYARAMAN, G. et al., FEBS Letters, 2000, vol. 482, no. 1-2, pages 154-58 (X) *

Also Published As

Publication number Publication date
EP2270038A2 (en) 2011-01-05
CY1112330T1 (el) 2015-12-09
PT1689775E (pt) 2011-10-13
SG149000A1 (en) 2009-01-29
EP2363411A1 (en) 2011-09-07
EP2270038A3 (en) 2011-02-23
ATA19522003A (de) 2004-12-15
ATE439376T1 (de) 2009-08-15
JP2007536906A (ja) 2007-12-20
NZ547612A (en) 2009-07-31
US7585937B2 (en) 2009-09-08
JP4980721B2 (ja) 2012-07-18
SI1689775T1 (sl) 2011-11-30
WO2005054285A1 (en) 2005-06-16
EP1752470B1 (en) 2009-08-12
DK1752470T3 (da) 2009-12-14
PL1689775T3 (pl) 2011-12-30
EP1752470A1 (en) 2007-02-14
EP1689775A1 (en) 2006-08-16
KR20070001917A (ko) 2007-01-04
US20110144305A1 (en) 2011-06-16
ATE515269T1 (de) 2011-07-15
IL175565A0 (en) 2006-09-05
JP2012165747A (ja) 2012-09-06
DE602004022595D1 (de) 2009-09-24
JP2012139226A (ja) 2012-07-26
US20080112926A1 (en) 2008-05-15
ES2330362T3 (es) 2009-12-09
KR101278459B1 (ko) 2013-07-01
ES2369139T3 (es) 2011-11-25
KR101188785B1 (ko) 2012-10-16
AU2004295104A1 (en) 2005-06-16
BRPI0416544A (pt) 2007-01-09
CY1109480T1 (el) 2014-08-13
US20090005541A1 (en) 2009-01-01
CN1890264A (zh) 2007-01-03
US20100331237A1 (en) 2010-12-30
KR20120063542A (ko) 2012-06-15
SI1752470T1 (sl) 2009-12-31
US7807413B2 (en) 2010-10-05
EP2311866A1 (en) 2011-04-20
PT1752470E (pt) 2009-10-15
CA2546789A1 (en) 2005-06-16
EP1689775B1 (en) 2011-07-06
AT412785B (de) 2005-07-25
PL1752470T3 (pl) 2010-01-29
DK1689775T3 (da) 2011-09-26
CN1890264B (zh) 2014-01-22

Similar Documents

Publication Publication Date Title
US7807413B2 (en) GAG binding protein
Lasagni et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4
Graham et al. Uncoupling of stem cell inhibition from monocyte chemoattraction in MIP‐1alpha by mutagenesis of the proteoglycan binding site.
US5652133A (en) Cloning and expression of the human macrophage inflammatory protein-1.alpha.α) /rantes receptor
JP5462623B2 (ja) Elr−cxcケモカインの高親和性アンタゴニスト
AU2002237136B2 (en) High-affinity antagonists of ELR-CXC chemokines
PL204231B1 (pl) Zastosowanie mutanta chemokiny CC, kompozycja farmaceutyczna do leczenia stwardnienia rozsianego, skrócona i zmutowana ludzka RANTES i sposób jej wytwarzania, cząsteczka DNA i zawierający ją wektor ekspresyjny oraz komórka gospodarza
KR19990063834A (ko) 단형 케모킨 베타-8
US7365171B2 (en) Chemokine-like factors (CKLFs) with chemotactic and hematopoietic stimulating activities
EP1034272A1 (en) A cDNA ENCODING C6 $g(b)-CHEMOKINE LEUKOTACTIN-1(Lkn-1) ISOLATED FROM HUMAN
Catusse et al. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6
KR100250090B1 (ko) 사람에서 분리한 c 6 베타-케모카인 lkn-2의 cdna 및재조합 lkn-2의 제조방법
Wain et al. Rapid site-directed mutagenesis of chemokines and their purification from a bacterial expression system
US20020007047A1 (en) Short forms of chemokine beta-8
Kwon et al. Characterization of CK
JPWO1998026071A1 (ja) ヒトcc型ケモカインelc

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired